On today’s episode of Higher Exchanges, Jesse Redmond and Morgan Paxhia sit down with Boris Jordan, Chairman and CEO of Curaleaf, the largest cannabis company in the world.

We discuss what may be the most important policy and capital markets moment the industry has seen in years. Boris shares Curaleaf’s perspective on federal rescheduling, what it could change for operators, when it may become final, and whether additional catalysts like SAFER banking, uplisting, or even descheduling could follow.

We also explore Curaleaf’s evolving strategy around hemp-derived THC. After entering the category in 2018, exiting in 2023, reentering in 2024, and now stepping away again, Boris explains what changed in the regulatory landscape and what conditions could bring Curaleaf back to hemp in the future.

The conversation then turns to capital markets and consolidation across the cannabis industry. Following Curaleaf’s recent $500M refinancing, we discuss the improving tone in financing markets, whether deal activity is returning, and where industry consolidation may emerge.

Finally, we dive into Curaleaf’s fundamentals, including the balance between U.S. and international growth, sustaining margins through years of price compression, and what investors may be missing when evaluating the largest operator in cannabis.

A thoughtful discussion on policy catalysts, industry structure, and the next phase of growth for cannabis.

Higher Exchanges is powered by Flowhub.

Topics Discussed

• Federal cannabis rescheduling and policy outlook

• SAFER banking, uplisting, and future catalysts

• The future of hemp-derived THC

• Cannabis capital markets and financing conditions

• Industry consolidation and M&A

• Curaleaf’s international growth strategy

• Margins and price compression in U.S. cannabis

• Curaleaf’s “Built for Growth” strategy